Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19

INTRODUCTION: The COVID-19 global pandemic caused by the novel coronavirus, SARS-CoV-2, and the consequent morbidity and mortality attributable to progressive hypoxemia and subsequent respiratory failure threaten to overrun hospital critical care units globally. New agents that address the hyperinfl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasky, Joseph A., Fuloria, Jyotsna, Morrison, Marion E., Lanier, Randall, Naderer, Odin, Brundage, Tom, Melemed, Allen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588947/
https://www.ncbi.nlm.nih.gov/pubmed/33108622
http://dx.doi.org/10.1007/s12325-020-01539-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588947/
https://www.ncbi.nlm.nih.gov/pubmed/33108622
http://dx.doi.org/10.1007/s12325-020-01539-z

Ejemplares similares